In a recent filing with the Securities and Exchange Commission, CannaPharmaRX, Inc. disclosed that Dean Medwid has stepped down as Chief Executive Officer (CEO) for personal reasons. The company, which operates in the pharmaceutical preparations industry under the trading symbol OTC Markets:CPMD, confirmed that Medwid's departure on September 9, 2024, was not due to any disagreements over operations, policies, or practices.
The Calgary-based company's Board of Directors is actively seeking a replacement for the CEO position. In the meantime, the board and the company's staff will collaboratively manage daily operations to ensure a smooth transition and minimal disruption. CannaPharmaRX expressed gratitude towards Medwid for his commitment and contributions during his tenure as CEO.
This executive change comes as CannaPharmaRX, known formerly as Golden Dragon Holding Co., CCVG, Inc., and Concord Ventures, Inc., continues to navigate the competitive pharmaceutical sector. The company's leadership transition is a significant event for stakeholders and could influence the company's strategic direction moving forward.
The information in this article is based on a press release statement from CannaPharmaRX filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.